Full-Time

AI Experience Design Lead

Updated on 9/12/2026

Deadline 9/13/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$176.6k - $294.3k/yr

+ 20% target bonus + Share-based long-term incentive program

No H1B Sponsorship

Collegeville, PA, USA + 1 more

More locations: New York, NY, USA

Hybrid

Hybrid work; occasional travel may be required, with flexibility to work across global time zones.

Category
Product & Experience Design (1)
Required Skills
LLM
Interaction Design
Agile
REST APIs
Web Development
Graphic Design
Product Design

Get referred to Pfizer

See people who can refer or advise you

Requirements
  • 10–15+ years of progressive experience in Experience Design, User Experience, or Product Design, with a proven track record of delivering complex, high-impact digital products and experiences in enterprise or highly matrixed environments.
  • 5+ years of direct people management experience, including hiring, developing, and leading high-performing design teams.
  • Working fluency with front-end development principles, application programming interfaces, and design-token pipelines, sufficient to partner with Engineering on delivering design standards as code.
  • Experience owning and evolving design systems and AI-first interaction patterns at scale to ensure scalability, consistency, and quality.
  • Deep expertise in AI-driven experience design, including hands-on experience designing Agentic AI workflows and Conversational User Experience for chat and/or voice, including dialog flows, conversation state management, repair and fallback patterns, escalation models, and human-in-the-loop controls.
  • Advanced understanding of how AI systems behave, communicate, and build trust, including experience designing transparency cues, explainability patterns, refusal behaviors, safety guardrails, and responsible AI interaction models.
  • Exceptional design judgment and craft excellence, with the ability to independently produce end-to-end design work from problem framing through high-fidelity, interactive, and executive-ready prototypes.
  • Outstanding executive communication and storytelling skills, including the ability to clearly articulate, justify, and defend design decisions to senior leadership and diverse stakeholder groups.
  • Expertise in accessibility and inclusive design, with hands-on experience ensuring Web Content Accessibility Guidelines 2.1 AA compliance across digital products and platforms.
  • Strong analytical and problem-solving skills, with the ability to synthesize qualitative and quantitative inputs into clear design direction and actionable insights.
  • A robust portfolio demonstrating system-level thinking, AI-powered experiences, and rapid prototyping approaches, including design standards or components shipped as production code.
  • Strong digital literacy and an AI-first mental model, with the ability to critically evaluate and integrate generative tools into the creative process to solve complex design challenges at scale.
  • Ability to manage multiple complex programs and projects simultaneously.
  • Candidates must be authorized to be employed in the United States by any employer.
  • This position requires permanent work authorization in the United States.
Responsibilities
  • Own, extend, and evolve Pfizer’s AI-first design system for the colleague experience across human and agent surfaces as the single source of truth for how Pfizer’s AI looks, sounds, and behaves.
  • Deliver design standards as code, including tokens, patterns, and components shipped into the engineering build pipeline, with accessibility built in.
  • Track adoption in code through pattern usage, override rate, and exception requests, and retire patterns the data shows are not working.
  • Connect design outcomes to measurable key performance indicators, including adoption, task success, trust, time-to-resolution, and first-pass compliance.
  • Continuously explore emerging AI capabilities, build functional prototypes in code, introduce emerging tools and methods, validate new approaches, and scale ways AI can improve the colleague experience.
  • Independently own end-to-end design execution for high-impact, ambiguous initiatives from problem framing through high-fidelity, interactive, and executive-ready prototypes.
  • Act as the design authority for Agentic AI experiences, including systems that plan, reason, invoke tools, and execute multi-step workflows with humans in the loop.
  • Own Conversational User Experience end-to-end for chat and/or voice, including dialog flows, conversation state, error recovery, escalation, and safe fallback behaviors.
  • Define assistant behaviors such as tone and voice, refusal patterns, transparency cues, and explainability, including edge cases and failure modes in regulated contexts.
  • Partner closely with AI, Data, Product, and Engineering teams to co-own Large Language Model-enabled products that balance autonomy, usability, safety, and trust.
  • Maintain a high design bar across interaction design, visual design, systems thinking, product thinking, and storytelling.
  • Serve as a trusted design advisor to Product, Engineering, and executive stakeholders and translate complex design and AI concepts into decisions leaders can act on.
  • Support product vision and roadmap prioritization by helping Product and Engineering partners evaluate which AI capabilities to build, sequence, or sunset based on user value and experience impact.
  • Build, lead, and grow a high-performing team of AI-native experience designers; set the hiring bar; define roles, levels, and growth paths; establish AI-native ways of working; and mentor direct reports by modeling the craft.
  • Own the team’s operating budget and staffing across platforms and initiatives and partner with Finance on annual planning.
  • Lead the practice’s exploration of new design tools and methods, experiment in the open, and bring validated techniques into the team’s standard ways of working.
  • Ship production design work that sets the bar for the team and demonstrates how AI-first design is executed.
  • Make decisions with appropriate context, start work proactively, improvise around missing inputs, and correct course using evidence from the work.
  • Hold a defensible point of view on visual and interaction style, including typography, motion, tone, and interaction detail.
  • Take accountability for experience quality and adoption on every surface the design system touches, including pattern reuse and first-pass compliance.
  • Work fluently across design, engineering, and AI; translate between design intent and technical implementation; and build team depth beyond a single specialty.
  • Set the standard for specification-driven design communication and present design rationale clearly to engineers and senior leadership.
  • Design patterns that scale across every platform and agent surface and connect design decisions to the broader experience, organization, and platform.
  • Oversee and guide the work of colleagues to achieve meaningful outcomes and create business impact.
  • Work across global time zones as needed.
Desired Qualifications
  • Strong product design experience, including partnering with Product and Engineering to shape scope, prioritize tradeoffs, and define measurable outcomes.
  • Hands-on experience building with Large Language Model application programming interfaces or agent frameworks to prototype real agent behavior in code rather than static interfaces.
  • Advanced prompt engineering skills using prompts as detailed creative briefs that set parameters, constraints, and brand identity.
  • Expertise working within lean or agile environments with fast-paced, iterative product cycles.
  • Track record of building design teams from the ground up, including hiring, onboarding, and career-pathing frameworks.
  • Experience with AI experience evaluation approaches, including conversation quality testing, scenario-based risk testing, and iterative improvement loops tied to product metrics.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose to $15 billion, and non-COVID products grew 5% operationally.
  • Pfizer raised 2026 guidance to $60.5 billion-$62.5 billion after Eliquis, Padcev, Vyndaqel strength.
  • Berobenatide entered Phase 3 planning, giving Pfizer a credible obesity franchise before 2028.

What critics are saying

  • Depo-Provera MDL exceeded 5,800 cases by July 2026, with late-2026 bellwethers looming.
  • Vyndamax still faces Apotex litigation in Delaware, preserving generic-entry uncertainty beyond 2031.
  • Ringaskiddy and Catania cuts show manufacturing contraction, signaling more restructuring through 2029.

What makes Pfizer unique

  • Seagen gives Pfizer leading ADCs: Padcev, Tivdak, Adcetris, Tucysa across oncology.
  • Pfizer still owns COMIRNATY distribution scale, with XFG vaccine approved August 27, 2026.
  • Vyndamax settlement extends U.S. exclusivity to June 1, 2031, stabilizing cardiomyopathy cash flows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

-5%

2 year growth

-5%
Yahoo Finance
Sep 10th, 2026
Medicus Pharma secures Pfizer ADC deal with $2M funding, advances SkinJect for rare cancer treatment

Medicus Pharma has secured a development and licensing agreement with Pfizer for a CD228-targeted antibody-drug conjugate programme focused on solid tumours, including refractory melanoma. Pfizer is providing approximately $2 million in development funding, plus inventory and infrastructure support. CEO Dr Raza Bokhari said the deal allows Medicus to continue from where Pfizer concluded its Phase 1 dose-escalation work, strengthening the company's position in precision oncology. Medicus is also advancing its SkinJect programme for basal cell carcinoma. Final clinical trial results identified the 200-microgram patch as the optimal dose for future studies. The company is preparing for the FDA-approved pivotal SkinJect 005 study whilst recruiting patients. An independent reimbursement analysis suggests SkinJect could achieve reimbursement levels of $25,000 or more per patient.

Yahoo Finance
Sep 8th, 2026
AbbVie beats Pfizer as top dividend stock with 53-year payout streak and 203% growth

AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.

Yahoo Finance
Aug 28th, 2026
Pfizer's updated COVID vaccine ships as FDA approves narrower rollout for over-65s and high-risk groups

Pfizer received FDA approval for its updated Comirnaty COVID-19 vaccine on Thursday, with deliveries to pharmacies and clinics beginning immediately. The company's shares were trading at $27.9079 on 28 August. However, the market opportunity has significantly narrowed from pandemic levels. Eligibility is now limited to adults aged 65 and older, plus higher-risk patients aged 5 through 64. Despite Comirnaty having distributed over five billion doses worldwide historically, today's revenue potential is considerably more constrained. Pfizer faces competition from Moderna and the Novavax-Sanofi protein vaccine for this smaller patient pool. The company's current share price sits 5.27% above its estimated value of $26.51, suggesting investors are paying a premium before actual uptake and commercial results become clear.

Associated Press
Aug 27th, 2026
FDA approves Pfizer-BioNTech XFG-adapted COVID-19 vaccine for high-risk groups

Pfizer and BioNTech have received US Food and Drug Administration (FDA) approval for their 2026-2027 COVID-19 vaccine targeting the XFG variant. The vaccine is approved for adults aged 65 and older, and individuals aged 5 to 64 with underlying conditions that increase risk of severe COVID-19 outcomes. The FDA approval is based on clinical, non-clinical and real-world data demonstrating the vaccine generates strong immune responses against currently circulating SARS-CoV-2 variants, including XFG and other contemporary lineages. The XFG variant was selected following FDA guidance for fall 2026 vaccine composition. The vaccine will begin shipping immediately and will be available in US pharmacies, hospitals and clinics within days. To date, more than five billion doses of COMIRNATY have been distributed globally.

Yahoo Finance
Aug 24th, 2026
Pfizer and J&J navigate patent cliffs with newer drugs offsetting blockbuster losses

Pfizer and Johnson & Johnson are navigating patent cliffs as key drugs lose exclusivity, with their latest results showing differing stages of transition. Pfizer's revenue excluding COVID products grew 5% operationally in Q2 2026, with newer medicines like Padcev and Vyndaqel contributing. The company expects $9.7 billion in cost savings through 2029 to support margins during the transition. Johnson & Johnson's Innovative Medicine sales rose 7.8%, despite Stelara revenue declining 55%. Tremfya sales surged 72.5% to $2 billion, helping offset losses alongside growth from oncology and neuroscience products. Johnson & Johnson raised 2026 guidance, with reported sales expected to reach $101.1 billion and adjusted EPS of $11.68. Its MedTech division provides additional diversification that pure pharmaceutical company Pfizer lacks, suggesting Johnson & Johnson's transition is more advanced.